News >

Adjuvant T-DM1 Approved in China for HER2+ Early Breast Cancer

Gina Columbus @ginacolumbusonc
Published: Thursday, Jan 23, 2020

Zhimin Shao, MD, director of the Institute of Oncology, Fudan University, director of the Breast Cancer Institute, director of Department of General Surgery, and director of Breast Surgery at the Affiliated Tumor Hospital of Fudan University

Zhimin Shao, MD

China’s State Administration of Drug Administration has approved ado-trastuzumab emtansine (T-DM1; Kadcyla), for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual disease following a neoadjuvant trastuzumab (Herceptin)-based regimen, according to an announcement by Roche China, the developer of the antibody-drug conjugate.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication